Advertisement

Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren’s syndrome

  • Adriana Cristiane Machado
  • Laura Caldas dos Santos
  • Tania FidelixEmail author
  • Ilda Lekwitch
  • Simone Barbosa Soares
  • André Felipe Gasparini
  • Juliana Venturini Augusto
  • Nelson Carvas Junior
  • Virginia Fernandes Moça Trevisani
Brief Report

Abstract

Sjögren’s syndrome is an autoimmune disease characterized by inflammation of the exocrine glands. The disease can be primary or secondary (if it is associated with another autoimmune disease). In Barring symptom management, there is no established treatment. To evaluate the effectiveness and safety of abatacept as a treatment of primary Sjögren’s syndrome over the course of 24 months. Eleven patients with primary Sjögren’s syndrome from the Rheumatology Department of Universidade Santo Amaro, Sao Paulo, Brazil were enrolled for a prospective observational study. Eligible participants were diagnosed according to the 2002 American-European consensus criteria and had a score greater than 3 on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). Participants received intravenous abatacept for 24 months at a weight-adjusted dose of 500 mg for patients weighing < 60 kg and 750 mg for those weighing > 60 kg. The outcomes were ESSDAI activity index, non-stimulated salivary flow rate, ocular dryness (Schirmer test, tear film break-up time, and ocular staining score), SF-36 questionnaire, and Fatigue domain of the FACIT (Functional Assessment of Chronic Illness Therapy) index. There was a statistically significant reduction in ESSDAI index and improvement of salivary flow. One subscale of the SF-36 index—emotional role functioning—showed improvement. There was no change in ocular parameters or in the FACIT index. In this sample of 11 patients with primary Sjögren’s syndrome, abatacept therapy improved xerostomia and systemic disease activity.

Key Points

Abatacept is safe and effective for the treatment of primary Sjögren’s syndrome.

Abatacept can improve salivary flow and ESSDAI index in this patient population.

Keywords

Abatacept Autoimmune diseases Sicca syndrome Sjögren’s syndrome Xerostomia 

Notes

Compliance with ethical standards

Disclosures

None

Ethical approval

The study was approved by the local Ethics Committee. All procedures were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients provided written informed consent for participation before undergoing any procedures.

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

References

  1. 1.
    Yannis A, Drosos AA (2012) Epidemiology. In: Ramos-Casals M, Stone JH, Moutsoupoulos HM (eds) Sjögren’s syndrome: diagnosis and therapeutics. Springer- Verlag, New York, pp 1–9Google Scholar
  2. 2.
    St. Clair EW (2017) Sjögren’s syndrome. In: Firestein GS, Gabriel SE, McInnes IB, O’ Dell JR (ed) Kelley & Firestein’s textbook of rheumatology. Elsevier, pp 1221–1244Google Scholar
  3. 3.
    Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X (2010) Treatment of primary Sjogren syndrome: a systematic review. JAMA 304:452–460.  https://doi.org/10.1001/jama.2010.1014 CrossRefGoogle Scholar
  4. 4.
    Retamozo S, Flores-Chavez A, Consuegra-Fernández M, Lozano F, Ramos-Casals M, Brito-Zeron P (2018) Cytokines as therapeutic targets in primary Sjögren syndrome. Pharmacol Ther 184:81–97.  https://doi.org/10.1016/j.pharmthera.2017.10.019 CrossRefGoogle Scholar
  5. 5.
    Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA 312:249–258.  https://doi.org/10.1001/jama.2014.7682 CrossRefGoogle Scholar
  6. 6.
    Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, Valdez IH, Kurrasch RH, Delapenha R, Jackson W (1993) Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 11:149–156Google Scholar
  7. 7.
    Price EJ, Rigby SP, Clancy U, Venables PJ (1998) A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 25:896–899Google Scholar
  8. 8.
    Willeke P, Schluter B, Becker H, Schotte H, Domschke W, Gaubitz M (2007) Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. Arthritis Res Ther 9:R115.  https://doi.org/10.1186/ar2322 CrossRefGoogle Scholar
  9. 9.
    Reiser H, Stadecker MJ (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369–1377.  https://doi.org/10.1056/NEJM199610313351807 CrossRefGoogle Scholar
  10. 10.
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H (2014) Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:1393–1396.  https://doi.org/10.1136/annrheumdis-2013-204653 CrossRefGoogle Scholar
  11. 11.
    Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dorner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, K LS, Smolen J, Laque RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C (2015) EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open 1:e000022.  https://doi.org/10.1136/rmdopen-2014-000022 CrossRefGoogle Scholar
  12. 12.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjogren's S (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558.  https://doi.org/10.1136/ard.61.6.554 CrossRefGoogle Scholar
  13. 13.
    Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR (1999) Validation of the Brazilian version of the generic six-dimensional short form quality of life questionnaire (SF-6D Brazil). Rev Bras Reumatol 39:143–150Google Scholar
  14. 14.
    Webster K, Odom L, Peterman A, Lent L, Cella D (1999) The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 8:604Google Scholar
  15. 15.
    Adler S, Koerner M, Foerger F, Caversaccio MD, Villiger PM (2013) Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res (Hoboken) 65:1862–1868CrossRefGoogle Scholar
  16. 16.
    Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, Yokosawa M, Yagishita M, Takahashi H, Kurata I, Ohyama A, Honda F, Asashima H, Miki H, Umeda N, Kondo Y, Hirata S, Saito K, Tanaka Y, Horai Y, Nakamura H, Kawakami A, Sumida T (2016) Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (rheumatoid arthritis with Orencia trial toward Sjogren's syndrome Endocrinopathy) trial. Mod Rheumatol 26:891–899.  https://doi.org/10.3109/14397595.2016.1158773 CrossRefGoogle Scholar
  17. 17.
    Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, Hendriks RW, Vissink A, Kroese FGM, Bootsma H (2017) Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjogren's syndrome. Arthritis Rheumatol 69:1850–1861.  https://doi.org/10.1002/art.40165 CrossRefGoogle Scholar
  18. 18.
    Bristol-Myers Squibb 2019. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous abatacept in adults with active primary Sjögren’s syndrome. https://ichgcp.net/clinical-trials-registry/NCT02915159. Accessed 07

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Adriana Cristiane Machado
    • 1
  • Laura Caldas dos Santos
    • 2
  • Tania Fidelix
    • 3
    • 4
    Email author
  • Ilda Lekwitch
    • 4
  • Simone Barbosa Soares
    • 5
  • André Felipe Gasparini
    • 5
  • Juliana Venturini Augusto
    • 5
  • Nelson Carvas Junior
    • 6
  • Virginia Fernandes Moça Trevisani
    • 7
    • 8
  1. 1.Rheumatology DepartmentUniversidade Santo Amaro (UNISA)São PauloBrazil
  2. 2.Universidade Federal de São Paulo (UNIFESP)São PauloBrazil
  3. 3.Department of Evidence-Based Health, UNIFESPSão PauloBrazil
  4. 4.RN, UNISASão PauloBrazil
  5. 5.UNISASão PauloBrazil
  6. 6.Universidade Paulista (UNIP)São PauloBrazil
  7. 7.Department of Evidence-Based Health, UNIFESPSão PauloBrazil
  8. 8.Rheumatology Department, UNISASão PauloBrazil

Personalised recommendations